# Catherine M Bollard

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 307 papers | 16,180 citations | 16451 64 h-index | 19749 117 g-index |
| 315 all docs | 315 docs citations | 315 times ranked | 13692 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | CD28 costimulation improves expansion and persistence of chimeric antigen receptorâ€"modified T cells in lymphoma patients. Journal of Clinical Investigation, 2011, 121, 1822-1826. | 8.2 | 876 |
| 2 | Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood, 2010, 115, 925-935. | 1.4 | 721 |
| 3 | Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nature Medicine, 2006, 12, 1160-1166. | 30.7 | 536 |
| 4 | Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood, 2013, 121, 5113-5123. | 1.4 | 507 |
| 5 | Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood, 2013, 122, 2965-2973. | 1.4 | 470 |
| 6 | Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins. Journal of Clinical Oncology, 2014, 32, 798-808. | 1.6 | 433 |
| 7 | Cord-Blood Engraftment with Ex Vivo Mesenchymal-Cell Coculture. New England Journal of Medicine, 2012, 367, 2305-2315. | 27.0 | 430 |
| 8 | Cytotoxic T Lymphocyte Therapy for Epstein-Barr Virus+ Hodgkin's Disease. Journal of Experimental Medicine, 2004, 200, 1623-1633. | 8.5 | 371 |
| 9 | Treatment of nasopharyngeal carcinoma with Epstein-Barr virusâ€"specific T lymphocytes. Blood, 2005, 105, 1898-1904. | 1.4 | 344 |
| 10 | Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood, 2009, 114, 4283-4292. | 1.4 | 311 |
| 11 | Adapting a transforming growth factor Î²â€"related tumor protection strategy to enhance antitumor immunity. Blood, 2002, 99, 3179-3187. | 1.4 | 310 |
| 12 | Clinical and immunological responses after CD30-specific chimeric antigen receptorâ€"redirected lymphocytes. Journal of Clinical Investigation, 2017, 127, 3462-3471. | 8.2 | 301 |
| 13 | Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood, 2007, 110, 2838-2845. | 1.4 | 266 |
| 14 | Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood, 2011, 117, 5835-5849. | 1.4 | 241 |
| 15 | Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood, 2009, 114, 1958-1967. | 1.4 | 235 |
| 16 | T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nature Reviews Clinical Oncology, 2012, 9, 510-519. | 27.6 | 230 |
| 17 | Adoptive Transfer of EBV-specific T Cells Results in Sustained Clinical Responses in Patients With Locoregional Nasopharyngeal Carcinoma. Journal of Immunotherapy, 2010, 33, 983-990. | 2.4 | 201 |
| 18 | Antitumor Activity of EBV-specific T Lymphocytes Transduced With a Dominant Negative TGF-Î² Receptor. Journal of Immunotherapy, 2008, 31, 500-505. | 2.4 | 197 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Epstein-Barr virusâ€"specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood, 2002, 99, 2009-2016. | 1.4 | 185 |
| 20 | Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nature Reviews Clinical Oncology, 2019, 16, 45-63. | 27.6 | 178 |
| 21 | T cells for viral infections after allogeneic hematopoietic stem cell transplant. Blood, 2016, 127, 3331-3340. | 1.4 | 177 |
| 22 | Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood, 2010, 116, 4700-4702. | 1.4 | 176 |
| 23 | Ultra Low-Dose IL-2 for GVHD Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation Mediates Expansion of Regulatory T Cells without Diminishing Antiviral and Antileukemic Activity. Clinical Cancer Research, 2014, 20, 2215-2225. | 7.0 | 176 |
| 24 | Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. British Journal of Haematology, 2017, 177, 457-466. | 2.5 | 158 |
| 25 | Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ T cells. Journal of Clinical Investigation, 2018, 128, 876-889. | 8.2 | 157 |
| 26 | Rituximab for High-Risk, Mature B-Cell Non-Hodgkinâ€™s Lymphoma in Children. New England Journal of Medicine, 2020, 382, 2207-2219. | 27.0 | 157 |
| 27 | Antigen Presenting Cell-Mediated Expansion of Human Umbilical Cord Blood Yields Log-Scale Expansion of Natural Killer Cells with Anti-Myeloma Activity. PLoS ONE, 2013, 8, e76781. | 2.5 | 155 |
| 28 | Targeting of GD2-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. International Journal of Cancer, 2001, 94, 228-236. | 5.1 | 143 |
| 29 | Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood, 2003, 102, 2292-2299. | 1.4 | 139 |
| 30 | Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. Journal of Clinical Oncology, 2018, 36, 1128-1139. | 1.6 | 137 |
| 31 | Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, 2305-2321. | 2.0 | 132 |
| 32 | Identification of Hexon-Specific CD4 and CD8 T-Cell Epitopes for Vaccine and Immunotherapy. Journal of Virology, 2008, 82, 546-554. | 3.4 | 129 |
| 33 | Current understanding of the role of Epsteinâ€"Barr virus in lymphomagenesis and therapeutic approaches to EBV-associated lymphomas. Leukemia and Lymphoma, 2008, 49, 27-34. | 1.3 | 124 |
| 34 | Prussian blue nanoparticle-based photothermal therapy combined with checkpoint inhibition for photothermal immunotherapy of neuroblastoma. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 771-781. | 3.3 | 122 |
| 35 | Acute exercise preferentially redeploys NK-cells with a highly-differentiated phenotype and augments cytotoxicity against lymphoma and multiple myeloma target cells. Brain, Behavior, and Immunity, 2014, 39, 160-171. | 4.1 | 121 |
| 36 | Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood, 2015, 125, 2885-2892. | 1.4 | 118 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes. Journal of Allergy and Clinical Immunology, 2016, 137, 1498-1505.e1. | 2.9 | 117 |
| 38 | SARS-CoV-2â€“specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein. Blood, 2020, 136, 2905-2917. | 1.4 | 108 |
| 39 | Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood, 2009, 113, 2442-2450. | 1.4 | 107 |
| 40 | Ultra-low Dose Interleukin-2 Promotes Immune-modulating Function of Regulatory T Cells and Natural Killer Cells in Healthy Volunteers. Molecular Therapy, 2014, 22, 1388-1395. | 8.2 | 106 |
| 41 | Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. Blood, 2010, 115, 2695-2703. | 1.4 | 105 |
| 42 | Outcomes of adults and children with primary mediastinal Bâ€cell lymphoma treated with doseâ€adjusted <scp>EPOCH</scp>â€R. British Journal of Haematology, 2017, 179, 739-747. | 2.5 | 101 |
| 43 | Most Closely HLA-Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL) to Treat Persistent Reactivation or Infection with Adenovirus, CMV and EBV After Hemopoietic Stem Cell Transplantation (HSCT). Blood, 2010, 116, 829-829. | 1.4 | 98 |
| 44 | Cord blood natural killer cells expressing a dominant negative TGF-Î² receptor: Implications for adoptive immunotherapy for glioblastoma. Cytotherapy, 2017, 19, 408-418. | 0.7 | 97 |
| 45 | The Generation and Characterization of LMP2-Specific CTLs for Use as Adoptive Transfer From Patients With Relapsed EBV-Positive Hodgkin Disease. Journal of Immunotherapy, 2004, 27, 317-327. | 2.4 | 96 |
| 46 | CMV-specific T cells generated from naÃ¯ve T cells recognize atypical epitopes and may be protective in vivo. Science Translational Medicine, 2015, 7, 285ra63. | 12.4 | 93 |
| 47 | Expanded Cytotoxic T-cell Lymphocytes Target the Latent HIV Reservoir. Journal of Infectious Diseases, 2015, 212, 258-263. | 4.0 | 86 |
| 48 | Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)â€“an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). Bone Marrow Transplantation, 2019, 54, 1868-1880. | 2.4 | 86 |
| 49 | Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, e76-e85. | 2.0 | 85 |
| 50 | ExÂvivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2RÎ³null mice. Experimental Hematology, 2012, 40, 445-456. | 0.4 | 84 |
| 51 | Generation of Tumor Antigen-Specific T Cell Lines from Pediatric Patients with Acute Lymphoblastic Leukemiaâ€"Implications for Immunotherapy. Clinical Cancer Research, 2013, 19, 5079-5091. | 7.0 | 81 |
| 52 | Cytotoxic T Lymphocytes Simultaneously Targeting Multiple Tumor-associated Antigens to Treat EBV Negative Lymphoma. Molecular Therapy, 2011, 19, 2258-2268. | 8.2 | 80 |
| 53 | Î²2-Adrenergic receptor signaling mediates the preferential mobilization of differentiated subsets of CD8+ T-cells, NK-cells and non-classical monocytes in response to acute exercise in humans. Brain, Behavior, and Immunity, 2018, 74, 143-153. | 4.1 | 80 |
| 54 | Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies. Blood, 2018, 132, 1438-1451. | 1.4 | 78 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Pediatric Lymphomas and Histiocytic Disorders of Childhood. Pediatric Clinics of North America, 2015, 62, 139-165. | 1.8 | 77 |
| 56 | BCL-2 antagonism sensitizes cytotoxic T cellâ€“resistant HIV reservoirs to elimination ex vivo. Journal of Clinical Investigation, 2020, 130, 2542-2559. | 8.2 | 77 |
| 57 | Adoptive immunotherapy for posttransplantation viral infections. Biology of Blood and Marrow Transplantation, 2004, 10, 143-155. | 2.0 | 76 |
| 58 | Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience. Cytotherapy, 2010, 12, 743-749. | 0.7 | 75 |
| 59 | Concise Review: Umbilical Cord Blood Transplantation: Past, Present, and Future. Stem Cells Translational Medicine, 2014, 3, 1435-1443. | 3.3 | 75 |
| 60 | Role of the tumor microenvironment in mature B-cell lymphoid malignancies. Haematologica, 2016, 101, 531-540. | 3.5 | 75 |
| 61 | A strategy for treatment of Epsteinâ€“Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells. Cancer Gene Therapy, 2004, 11, 81-91. | 4.6 | 74 |
| 62 | Characterization of Latent Membrane Protein 2 Specificity in CTL Lines from Patients with EBV-Positive Nasopharyngeal Carcinoma and Lymphoma. Journal of Immunology, 2005, 175, 4137-4147. | 0.8 | 72 |
| 63 | Improving T-cell Therapy for Relapsed EBV-Negative Hodgkin Lymphoma by Targeting Upregulated MAGE-A4. Clinical Cancer Research, 2011, 17, 7058-7066. | 7.0 | 72 |
| 64 | Virus-Specific T Cells for the Immunocompromised Patient. Frontiers in Immunology, 2017, 8, 1272. | 4.8 | 72 |
| 65 | How I treat T-cell chronic active Epstein-Barr virus disease. Blood, 2018, 131, 2899-2905. | 1.4 | 72 |
| 66 | Controlling Cytomegalovirus: Helping the Immune System Take the Lead. Viruses, 2014, 6, 2242-2258. | 3.3 | 66 |
| 67 | The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care. Cytotherapy, 2014, 16, 149-159. | 0.7 | 66 |
| 68 | A novel latent membrane 2 transcript expressed in Epstein-Barr virusâ€“positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy. Blood, 2010, 116, 3695-3704. | 1.4 | 63 |
| 69 | Generation of Polyclonal CMV-specific T Cells for the Adoptive Immunotherapy of Glioblastoma. Journal of Immunotherapy, 2012, 35, 159-168. | 2.4 | 59 |
| 70 | Cord Blood Natural Killer Cells Exhibit Impaired Lytic Immunological Synapse Formation That Is Reversed With IL-2 Exvivo Expansion. Journal of Immunotherapy, 2010, 33, 684-696. | 2.4 | 58 |
| 71 | Conjugating Prussian blue nanoparticles onto antigen-specific T cells as a combined nanoimmunotherapy. Nanomedicine, 2016, 11, 1759-1767. | 3.3 | 56 |
| 72 | Immunotherapy of Relapsed and Refractory Solid Tumors With Ex Vivo Expanded Multi-Tumor Associated Antigen Specific Cytotoxic T Lymphocytes: A Phase I Study. Journal of Clinical Oncology, 2019, 37, 2349-2359. | 1.6 | 56 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Third-party umbilical cord bloodâ€“derived regulatory T cells prevent xenogenic graft-versus-host disease. Cytotherapy, 2014, 16, 90-100. | 0.7 | 53 |
| 74 | The effects of age and latent cytomegalovirus infection on the redeployment of CD8+ T cell subsets in response to acute exercise in humans. Brain, Behavior, and Immunity, 2014, 39, 142-151. | 4.1 | 53 |
| 75 | Engineering the TGFÎ² Receptor to Enhance the Therapeutic Potential of Natural Killer Cells as an Immunotherapy for Neuroblastoma. Clinical Cancer Research, 2019, 25, 4400-4412. | 7.0 | 52 |
| 76 | General and Virus-Specific Immune Cell Reconstitution after Double Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 1284-1290. | 2.0 | 51 |
| 77 | Adenoviral Infections in Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2006, 12, 243-251. | 2.0 | 50 |
| 78 | Expansion of T cells targeting multiple antigens of cytomegalovirus, Epsteinâ€“Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation. Cytotherapy, 2011, 13, 976-986. | 0.7 | 50 |
| 79 | Post-Transplant Lymphoproliferative Disease in Pediatric Solid Organ Transplant Recipients. Pediatric Hematology and Oncology, 2013, 30, 520-531. | 0.8 | 50 |
| 80 | EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation. Blood, 2018, 132, 2351-2361. | 1.4 | 49 |
| 81 | Introduction to a review series on therapeutic antibodies. Blood, 2018, 131, 1-1. | 1.4 | 47 |
| 82 | Broadly-specific Cytotoxic T Cells Targeting Multiple HIV Antigens Are Expanded From HIV+ Patients: Implications for Immunotherapy. Molecular Therapy, 2015, 23, 387-395. | 8.2 | 46 |
| 83 | Comparable Outcome of Alternative Donor and Matched Sibling Donor Hematopoietic Stem Cell Transplant for Children with Acute Lymphoblastic Leukemia in First or Second Remission Using Alemtuzumab in a Myeloablative Conditioning Regimen. Biology of Blood and Marrow Transplantation, 2008, 14, 1245-1252. | 2.0 | 45 |
| 84 | Matched Related and Unrelated Donor Hematopoietic Stem Cell Transplantation for DOCK8 Deficiency. Biology of Blood and Marrow Transplantation, 2015, 21, 1037-1045. | 2.0 | 45 |
| 85 | Virus-specific T-cell therapies for patients with primary immune deficiency. Blood, 2020, 135, 620-628. | 1.4 | 45 |
| 86 | Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients with Antibody Deficiency. Journal of Clinical Immunology, 2021, 41, 1146-1153. | 3.8 | 45 |
| 87 | Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma. Journal of Clinical Oncology, 2022, 40, 2106-2118. | 1.6 | 45 |
| 88 | Assessing the Safety of Cytotoxic T Lymphocytes Transduced With a Dominant Negative Transforming Growth Factor-Î² Receptor. Journal of Immunotherapy, 2006, 29, 250-260. | 2.4 | 44 |
| 89 | Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphoma. Leukemia and Lymphoma, 2010, 51, 870-880. | 1.3 | 44 |
| 90 | Adoptive T-Cell Therapy for EBV-Associated Post-Transplant Lymphoproliferative Disease. Acta Haematologica, 2003, 110, 139-148. | 1.4 | 43 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | T-cell therapies for HIV. Immunotherapy, 2013, 5, 407-414. | 2.0 | 43 |
| 92 | Rare Pediatric Non-Hodgkin Lymphomas: A Report From Children's Oncology Group Study ANHL 04B1. Pediatric Blood and Cancer, 2016, 63, 794-800. | 1.5 | 43 |
| 93 | Improving T-Cell Therapy for Epstein-Barr Virus Lymphoproliferative Disorders. Journal of Clinical Oncology, 2013, 31, 5-7. | 1.6 | 42 |
| 94 | Complementation of Antigen-presenting Cells to Generate T Lymphocytes With Broad Target Specificity. Journal of Immunotherapy, 2014, 37, 193-203. | 2.4 | 42 |
| 95 | Fucosylation with fucosyltransferase VI or fucosyltransferase VII improves cord blood engraftment. Cytotherapy, 2014, 16, 84-89. | 0.7 | 42 |
| 96 | Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Childrenâ€™s Oncology Group AALL0434. Journal of Clinical Oncology, 2020, 38, 3062-3070. | 1.6 | 42 |
| 97 | Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1. Blood, 2021, 137, 3595-3603. | 1.4 | 40 |
| 98 | Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epsteinâ€"Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant. Cytotherapy, 2012, 14, 7-11. | 0.7 | 39 |
| 99 | ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children. European Journal of Cancer, 2019, 110, 74-85. | 2.8 | 39 |
| 100 | Frontiers in cancer immunotherapyâ€"a symposium report. Annals of the New York Academy of Sciences, 2021, 1489, 30-47. | 3.8 | 39 |
| 101 | Adoptive Tâ€cell transfer in cancer immunotherapy. Immunology and Cell Biology, 2006, 84, 281-289. | 2.3 | 38 |
| 102 | Acute exercise preferentially redeploys NK-cells with a highly-differentiated phenotype and augments cytotoxicity against lymphoma and multiple myeloma target cells. Part II: Impact of latent cytomegalovirus infection and catecholamine sensitivity. Brain, Behavior, and Immunity, 2015, 49, 59-65. | 4.1 | 38 |
| 103 | Toward a Rapid Production of Multivirus-Specific T Cells Targeting BKV, Adenovirus, CMV, and EBV from Umbilical Cord Blood. Molecular Therapy - Methods and Clinical Development, 2017, 5, 13-21. | 4.1 | 38 |
| 104 | Mobilizing Immune Cells With Exercise for Cancer Immunotherapy. Exercise and Sport Sciences Reviews, 2017, 45, 163-172. | 3.0 | 37 |
| 105 | Virus-Specific T Cells: Broadening Applicability. Biology of Blood and Marrow Transplantation, 2018, 24, 13-18. | 2.0 | 37 |
| 106 | T-cell therapies for HIV: Preclinical successes and current clinical strategies. Cytotherapy, 2016, 18, 931-942. | 0.7 | 36 |
| 107 | Vigorous exercise mobilizes CD34+ hematopoietic stem cells to peripheral blood via the Î²2-adrenergic receptor. Brain, Behavior, and Immunity, 2018, 68, 66-75. | 4.1 | 36 |
| 108 | Systemic Î²-Adrenergic Receptor Activation Augments the ex vivo Expansion and Anti-Tumor Activity of VÎ³9VÎ´2 T-Cells. Frontiers in Immunology, 2019, 10, 3082. | 4.8 | 36 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Human cytomegalovirus infection and the immune response to exercise. Exercise Immunology Review, 2016, 22, 8-27. | 0.4 | 36 |
| 110 | Children's Oncology Group's 2013 blueprint for research: Nonâ€Hodgkin lymphoma. Pediatric Blood and Cancer, 2013, 60, 979-984. | 1.5 | 35 |
| 111 | Hodgkin Disease and the Role of the Immune System. Pediatric Hematology and Oncology, 2011, 28, 176-186. | 0.8 | 34 |
| 112 | Functionally Active HIV-Specific T Cells that Target Gag and Nef Can Be Expanded from Virus-NaÃ¯ve Donors and Target a Range of Viral Epitopes: Implications for a Cure Strategy after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 536-541. | 2.0 | 34 |
| 113 | Human parainfluenza virus-3 can be targeted by rapidly ex vivo expanded T lymphocytes. Cytotherapy, 2016, 18, 1515-1524. | 0.7 | 33 |
| 114 | HIV-Specific, ExÂVivo Expanded T Cell Therapy: Feasibility, Safety, and Efficacy in ART-Suppressed HIV-Infected Individuals. Molecular Therapy, 2018, 26, 2496-2506. | 8.2 | 32 |
| 115 | Medulloblastoma rendered susceptible to NK-cell attack by TGFÎ² neutralization. Journal of Translational Medicine, 2019, 17, 321. | 4.4 | 32 |
| 116 | Quantitative activation suppression assay to evaluate human bone marrowâ€"derived mesenchymal stromal cell potency. Cytotherapy, 2015, 17, 1675-1686. | 0.7 | 31 |
| 117 | T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effect. Haematologica, 2015, 100, 709-719. | 3.5 | 30 |
| 118 | T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects. Journal of Clinical Oncology, 2021, 39, 1415-1425. | 1.6 | 30 |
| 119 | Vorinostat Renders the Replication-Competent Latent Reservoir of Human Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8 T Cells. EBioMedicine, 2017, 23, 52-58. | 6.1 | 29 |
| 120 | Tâ€cell receptor sequencing demonstrates persistence of virusâ€specific T cells after antiviral immunotherapy. British Journal of Haematology, 2019, 187, 206-218. | 2.5 | 29 |
| 121 | Emerging trends in COVID-19 treatment: learning from inflammatory conditions associated with cellular therapies. Cytotherapy, 2020, 22, 474-481. | 0.7 | 29 |
| 122 | Graft Versus Leukemia Response Without Graft-versus-host Disease Elicited By Adoptively Transferred Multivirus-specific T-cells. Molecular Therapy, 2015, 23, 179-183. | 8.2 | 28 |
| 123 | In vivoexpansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation. Leukemia and Lymphoma, 2006, 47, 837-842. | 1.3 | 27 |
| 124 | Improving clinical outcomes using adoptively transferred immune cells from umbilical cord blood. Cytotherapy, 2010, 12, 713-720. | 0.7 | 27 |
| 125 | Adoptive T Cell Therapy for Epsteinâ€"Barr Virus Complications in Patients With Primary Immunodeficiency Disorders. Frontiers in Immunology, 2018, 9, 556. | 4.8 | 27 |
| 126 | Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients. Blood Advances, 2019, 3, 2057-2068. | 5.2 | 27 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | A single bout of dynamic exercise enhances the expansion of MAGE-A4 and PRAME-specific cytotoxic T-cells from healthy adults. Exercise Immunology Review, 2015, 21, 144-53. | 0.4 | 27 |
| 128 | Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE). BMJ Open, 2020, 10, e034629. | 1.9 | 26 |
| 129 | Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restricted. Blood Advances, 2021, 5, 3309-3321. | 5.2 | 26 |
| 130 | Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epsteinâ€“Barr virus-associated lymphoma. Cytotherapy, 2011, 13, 518-522. | 0.7 | 25 |
| 131 | Pediatric Burkitt's Lymphoma and Diffuse B-Cell Lymphoma: Are Surveillance Scans Required?. Pediatric Hematology and Oncology, 2014, 31, 253-257. | 0.8 | 25 |
| 132 | Indocyanine Green-Nexturastat A-PLGA Nanoparticles Combine Photothermal and Epigenetic Therapy for Melanoma. Nanomaterials, 2020, 10, 161. | 4.1 | 25 |
| 133 | Overcoming T-cell exhaustion in LCH: PD-1 blockade and targeted MAPK inhibition are synergistic in a mouse model of LCH. Blood, 2021, 137, 1777-1791. | 1.4 | 25 |
| 134 | Proteogenomic discovery of neoantigens facilitates personalized multi-antigen targeted T cell immunotherapy for brain tumors. Nature Communications, 2021, 12, 6689. | 12.8 | 25 |
| 135 | Immunotherapy targeting EBV-expressing lymphoproliferative diseases. Best Practice and Research in Clinical Haematology, 2008, 21, 405-420. | 1.7 | 24 |
| 136 | A New Method for Reactivating and Expanding T Cells Specific for Rhizopus oryzae. Molecular Therapy - Methods and Clinical Development, 2018, 9, 305-312. | 4.1 | 24 |
| 137 | Designing Magnetically Responsive Biohybrids Composed of Cord Blood-Derived Natural Killer Cells and Iron Oxide Nanoparticles. Bioconjugate Chemistry, 2019, 30, 552-560. | 3.6 | 24 |
| 138 | Autologous Designer Antigen-presenting Cells by Gene Modification of T Lymphocyte Blasts With IL-7 and IL-12. Journal of Immunotherapy, 2007, 30, 506-516. | 2.4 | 23 |
| 139 | A single bout of dynamic exercise by healthy adults enhances the generation of monocyte-derived-dendritic cells. Cellular Immunology, 2015, 295, 52-59. | 3.0 | 23 |
| 140 | A single exercise bout enhances the manufacture of viral-specific T-cells from healthy donors: implications for allogeneic adoptive transfer immunotherapy. Scientific Reports, 2016, 6, 25852. | 3.3 | 22 |
| 141 | Successful Treatment of Stem Cell Graft Failure in Pediatric Patients Using a Submyeloablative Regimen of Campath-1H and Fludarabine. Biology of Blood and Marrow Transplantation, 2008, 14, 1298-1304. | 2.0 | 21 |
| 142 | The Development of a Myeloablative, Reduced-Toxicity, Conditioning Regimen for Cord Blood Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, e1-e5. | 0.4 | 21 |
| 143 | A single exercise bout augments adenovirus-specific T-cell mobilization and function. Physiology and Behavior, 2018, 194, 56-65. | 2.1 | 21 |
| 144 | Cell therapies for hematological malignancies: don't forget non-gene-modified t cells!. Blood Reviews, 2018, 32, 203-224. | 5.7 | 21 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus. Journal of Visualized Experiments, 2012, , e3627. | 0.3 | 20 |
| 146 | Cytotoxic T lymphocytes for leukemia and lymphoma. Hematology American Society of Hematology Education Program, 2014, 2014, 565-569. | 2.5 | 20 |
| 147 | Engineering cord blood to improve engraftment after cord blood transplant. Stem Cell Investigation, 2017, 4, 41-41. | 3.0 | 20 |
| 148 | Administration of Latent Membrane Protein 2â€"Specific Cytotoxic T Lymphocytes to Patients with Relapsed Epstein-Barr Virusâ€"Positive Lymphoma. Clinical Lymphoma and Myeloma, 2006, 6, 342-347. | 1.4 | 19 |
| 149 | De novo T-lymphocyte responses against baculovirus-derived recombinant influenzavirus hemagglutinin generated by a naive umbilical cord blood model of dendritic cell vaccination. Vaccine, 2009, 27, 1479-1484. | 3.8 | 19 |
| 150 | Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients. Blood Advances, 2020, 4, 5745-5754. | 5.2 | 19 |
| 151 | The generation and application of antigen-specific TÂcell therapies for cancer and viral-associated disease. Molecular Therapy, 2022, 30, 2130-2152. | 8.2 | 19 |
| 152 | Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT. Blood Advances, 2022, 6, 2520-2534. | 5.2 | 19 |
| 153 | Adoptive immunotherapy with the use of regulatory T cells and virus-specific T cells derived from cord blood. Cytotherapy, 2015, 17, 749-755. | 0.7 | 18 |
| 154 | HIV-Specific T Cells Generated from Naive T Cells Suppress HIV InÂVitro and Recognize Wide Epitope Breadths. Molecular Therapy, 2018, 26, 1435-1446. | 8.2 | 18 |
| 155 | Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II Trial. Journal of Clinical Oncology, 2021, 39, 3716-3724. | 1.6 | 18 |
| 156 | Sobering realities of surviving Hodgkin Lymphoma. Blood, 2011, 117, 1772-1773. | 1.4 | 17 |
| 157 | EBV+ lymphoproliferative diseases: opportunities for leveraging EBV as a therapeutic target. Blood, 2022, 139, 983-994. | 1.4 | 17 |
| 158 | Noninvasive Bioluminescent Imaging Demonstrates Long-Term Multilineage Engraftment of Ex Vivo-Expanded CD34-Selected Umbilical Cord Blood Cells. Stem Cells, 2009, 27, 1932-1940. | 3.2 | 16 |
| 159 | Cord Blood Graft Engineering. Biology of Blood and Marrow Transplantation, 2013, 19, S74-S78. | 2.0 | 16 |
| 160 | Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances. Therapeutic Advances in Hematology, 2015, 6, 295-307. | 2.5 | 16 |
| 161 | EBV-Directed T Cell Therapeutics for EBV-Associated Lymphomas. Methods in Molecular Biology, 2017, 1532, 255-265. | 0.9 | 16 |
| 162 | Virus-Specific T Cells: Current and Future Use in Primary Immunodeficiency Disorders. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 809-818. | 3.8 | 16 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | HIV-Specific T Cells Can Be Generated against Non-escaped T Cell Epitopes with a GMP-Compliant Manufacturing Platform. Molecular Therapy - Methods and Clinical Development, 2020, 16, 11-20. | 4.1 | 16 |
| 164 | NK Cell Adoptive Immunotherapy of Cancer: Evaluating Recognition Strategies and Overcoming Limitations. Transplantation and Cellular Therapy, 2021, 27, 21-35. | 1.2 | 16 |
| 165 | Multi-Virus-Specific T-Cell Therapy For Patients After Hematopoietic Stem Cell and Cord Blood Transplantation. Blood, 2013, 122, 140-140. | 1.4 | 16 |
| 166 | Challenges in the harmonization of immune monitoring studies and trial design for cell-based therapies in the context of hematopoietic cell transplantation for pediatric cancer patients. Cytotherapy, 2015, 17, 1667-1674. | 0.7 | 15 |
| 167 | Human papilloma virusâ€"specific T cells can be generated from naÃ¯ve T cells for use as an immunotherapeutic strategy for immunocompromised patients. Cytotherapy, 2018, 20, 385-393. | 0.7 | 15 |
| 168 | Generation of Norovirus-Specific T Cells From Human Donors With Extensive Cross-Reactivity to Variant Sequences: Implications for Immunotherapy. Journal of Infectious Diseases, 2020, 221, 578-588. | 4.0 | 15 |
| 169 | Assessment of ST2 for risk of death following graft-versus-host disease in pediatric and adult age groups. Blood, 2020, 135, 1428-1437. | 1.4 | 15 |
| 170 | Imaging of subclinical haemopoiesis after stem-cell transplantation in patients with haematological malignancies: a prospective pilot study. Lancet Haematology,the, 2018, 5, e44-e52. | 4.6 | 14 |
| 171 | Mesenchymal Stem Cell (MSC) Based Cord Blood (CB) Expansion (Exp) Leads to Rapid Engraftment of Platelets and Neutrophils. Blood, 2010, 116, 362-362. | 1.4 | 14 |
| 172 | SARS-CoV-2-Specific T Cell Responses Are Stronger in Children With Multisystem Inflammatory Syndrome Compared to Children With Uncomplicated SARS-CoV-2 Infection. Frontiers in Immunology, 2021, 12, 793197. | 4.8 | 14 |
| 173 | Novel Cord Blood Transplant Therapies. Biology of Blood and Marrow Transplantation, 2011, 17, S39-S45. | 2.0 | 13 |
| 174 | Cellular therapy for sickle cell disease. Cytotherapy, 2016, 18, 1360-1369. | 0.7 | 13 |
| 175 | ROR1 and ROR2â€"novel targets for neuroblastoma. Pediatric Hematology and Oncology, 2019, 36, 352-364. | 0.8 | 13 |
| 176 | Immunotherapy for Lymphoma Using T Cells Targeting Multiple Tumor Associated Antigens. Blood, 2015, 126, 186-186. | 1.4 | 13 |
| 177 | The coming of age of adoptive T-cell therapy for viral infection after stem cell transplantation. Annals of Translational Medicine, 2015, 3, 62. | 1.7 | 13 |
| 178 | Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplant. Blood Advances, 2022, 6, 2897-2907. | 5.2 | 13 |
| 179 | Cellular therapies for the treatment and prevention of SARS-CoV-2 infection. Blood, 2022, 140, 208-221. | 1.4 | 13 |
| 180 | Enhancing Immune Reconstitution: From Bench to Bedside. Biology of Blood and Marrow Transplantation, 2013, 19, S79-S83. | 2.0 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study. Annals of Hematology, 2021, 100, 2529-2539. | 1.8 | 12 |
| 182 | Novel TCR-like CAR-T cells targeting an HLAâˆ—0201-restricted SSX2 epitope display strong activity against acute myeloid leukemia. Molecular Therapy - Methods and Clinical Development, 2021, 23, 296-306. | 4.1 | 12 |
| 183 | Gene-Marking studies of hematopoietic cells. International Journal of Hematology, 2001, 73, 14-22. | 1.6 | 11 |
| 184 | Scouting out the neighborhood in AIDS-related lymphoma. Blood, 2013, 122, 306-307. | 1.4 | 11 |
| 185 | Gene Modification of Human Natural Killer Cells Using a Retroviral Vector. Methods in Molecular Biology, 2016, 1441, 203-213. | 0.9 | 11 |
| 186 | Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility study. Lancet HIV,the, 2020, 7, e602-e610. | 4.7 | 11 |
| 187 | Tumor-associated antigenâ€"specific T cells with nivolumab are safe and persist in vivo in relapsed/refractory Hodgkin lymphoma. Blood Advances, 2022, 6, 473-485. | 5.2 | 11 |
| 188 | High risk of relapsed disease in patients with NK/T-cell chronic active Epstein-Barr virus disease outside of Asia. Blood Advances, 2022, 6, 452-459. | 5.2 | 11 |
| 189 | Off-the-Shelf Third-Party Virus-Specific T Cell Therapy to Treat JC Polyomavirus Infection in Hematopoietic Stem Cell Transplantation Recipients. Transplantation and Cellular Therapy, 2022, 28, 116.e1-116.e7. | 1.2 | 11 |
| 190 | T-Cell Therapies for Epstein-Barr Virusâ€"Associated Lymphomas. Pediatric Hematology and Oncology, 2011, 28, 627-639. | 0.8 | 10 |
| 191 | Low rate of infusional toxicity after expanded cord blood transplantation. Cytotherapy, 2014, 16, 1153-1157. | 0.7 | 10 |
| 192 | Adoptive T Cell Immunotherapy for Patients with Primary Immunodeficiency Disorders. Current Allergy and Asthma Reports, 2017, 17, 3. | 5.3 | 10 |
| 193 | T-cell therapies for T-cell lymphoma. Cytotherapy, 2019, 21, 935-942. | 0.7 | 10 |
| 194 | Generation of Zika virusâ€"specific T cells from seropositive and virus-naÃ¯ve donors for potential use as an autologous or â€œoff-the-shelfâ€• immunotherapeutic. Cytotherapy, 2019, 21, 840-855. | 0.7 | 10 |
| 195 | Driving the CAR to the Bone Marrow Transplant Program. Current Hematologic Malignancy Reports, 2019, 14, 561-569. | 2.3 | 10 |
| 196 | Engineered Antigen-Specific T Cells Secreting Broadly Neutralizing Antibodies: Combining Innate and Adaptive Immune Response against HIV. Molecular Therapy - Methods and Clinical Development, 2020, 19, 78-88. | 4.1 | 10 |
| 197 | Identification of new cytokine combinations for antigen-specific T-cell therapy products via a high-throughput multi-parameter assay. Cytotherapy, 2021, 23, 65-76. | 0.7 | 10 |
| 198 | Cranial Radiation Can be Eliminated in Most Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Bortezomib Potentially Improves Survival in Children with T-Cell Lymphoblastic Lymphoma (T-LL): Results of Children's Oncology Group (COG) Trial AALL1231. Blood, 2020, 136, 11-12. | 1.4 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | PR1-specific cytotoxic T lymphocytes are relatively frequent in umbilical cord blood and can be effectively expanded to target myeloid leukemia. Cytotherapy, 2016, 18, 995-1001. | 0.7 | 9 |
| 200 | Beyond Chemotherapy: Checkpoint Inhibition and Cell-Based Therapy in Non-Hodgkin Lymphoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 592-603. | 3.8 | 9 |
| 201 | A participant-derived xenograft model of HIV enables long-term evaluation of autologous immunotherapies. Journal of Experimental Medicine, 2021, 218, . | 8.5 | 9 |
| 202 | Immunotherapy: opportunities, risks and future perspectives. Cytotherapy, 2014, 16, S120-S129. | 0.7 | 8 |
| 203 | Will Post-Transplantation Cell Therapies for Pediatric Patients Become Standard of Care?. Biology of Blood and Marrow Transplantation, 2015, 21, 402-411. | 2.0 | 8 |
| 204 | Virus-Specific T Cell Therapies for HIV: Lessons Learned From Hematopoietic Stem Cell Transplantation. Frontiers in Cellular and Infection Microbiology, 2020, 10, 298. | 3.9 | 8 |
| 205 | Phase II study of ex vivo expanded cord blood natural killer cells for multiple myeloma.. Journal of Clinical Oncology, 2018, 36, 8006-8006. | 1.6 | 8 |
| 206 | Developing T-cell therapies for lymphoma without receptor engineering. Blood Advances, 2017, 1, 2579-2590. | 5.2 | 7 |
| 207 | Reprint of: Virus-Specific T Cells: Broadening Applicability. Biology of Blood and Marrow Transplantation, 2018, 24, S1-S6. | 2.0 | 7 |
| 208 | Introduction to a review series on emerging immunotherapies for hematologic diseases. Blood, 2018, 131, 2617-2620. | 1.4 | 7 |
| 209 | Cancer Moonshot Immuno-Oncology Translational Network (IOTN): accelerating the clinical translation of basic discoveries for improving immunotherapy and immunoprevention of cancer. , 2020, 8, e000796. | | 7 |
| 210 | Identification of novel HLA-restricted preferentially expressed antigen in melanoma peptides to facilitate off-the-shelf tumor-associated antigen-specific T-cell therapies. Cytotherapy, 2021, 23, 694-703. | 0.7 | 7 |
| 211 | Adoptive Immunotherapy For Leukemia With Ex vivo Expanded T Cells. Current Drug Targets, 2017, 18, 271-280. | 2.1 | 7 |
| 212 | Immune-Based Therapies Targeting Mage-A4 for Relapsed/Refractory Hodgkin's Lymphoma After Stem Cell Transplant.. Blood, 2009, 114, 4089-4089. | 1.4 | 7 |
| 213 | Antiviral T Cells for Adenovirus in the Pretransplant Period: A Bridge Therapy for Severe Combined Immunodeficiency. Biology of Blood and Marrow Transplantation, 2018, 24, 1944-1946. | 2.0 | 6 |
| 214 | Defining the Inflammatory Plasma Proteome in Pediatric Hodgkin Lymphoma. Cancers, 2020, 12, 3603. | 3.7 | 6 |
| 215 | Hematopoietic Cell Transplantation: Practice Predictions for the Year 2023. Transplantation and Cellular Therapy, 2021, 27, 183.e1-183.e7. | 1.2 | 6 |
| 216 | Spike-directed vaccination elicits robust spike-specific T-cell response, including to mutant strains. Cytotherapy, 2022, 24, 10-15. | 0.7 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 217 | Gene therapy for paediatric leukaemia. Expert Opinion on Biological Therapy, 2001, 1, 663-674. | 3.1 | 5 |
| 218 | Aggressive peripheral CD70â€positive tâ€cell lymphoma associated with severe chronic active EBV infection. Pediatric Blood and Cancer, 2012, 59, 758-761. | 1.5 | 5 |
| 219 | Complete remissions post infusion of multiple tumor antigen specific T cells for the treatment of high risk leukemia and lymphoma patients after HCT. Cytotherapy, 2017, 19, e3. | 0.7 | 5 |
| 220 | Characterization of natural killer cells expressing markers associated with maturity and cytotoxicity in children and young adults with sickle cell disease. Pediatric Blood and Cancer, 2019, 66, e27601. | 1.5 | 5 |
| 221 | Complement inhibition does not impair the clinical antiviral capabilities of virus-specific T-cell therapy. Blood Advances, 2020, 4, 3252-3257. | 5.2 | 5 |
| 222 | The effects of Î²1 and Î²1+2 adrenergic receptor blockade on the exercise-induced mobilization and ex vivo expansion of virus-specific T cells: implications for cellular therapy and the anti-viral immune effects of exercise. Cell Stress and Chaperones, 2020, 25, 993-1012. | 2.9 | 5 |
| 223 | Chimeric antigen receptor-engineered natural killer cells: a promising cancer immunotherapy. Expert Review of Clinical Immunology, 2021, 17, 643-659. | 3.0 | 5 |
| 224 | Presentation of Epstein Barr Virus (EBV) Epitopes by Activated Human Î³Î´ T Cells Induces Peptide-Specific Cytolytic CD8+ T Cell Expansion.. Blood, 2006, 108, 1738-1738. | 1.4 | 5 |
| 225 | The Histone Deacetylase (HDAC) Inhibitor Entinostat (SNDX-275) Targets Hodgkin Lymphoma through a Dual Mechanism of Immune Modulation and Apoptosis Induction.. Blood, 2009, 114, 1562-1562. | 1.4 | 5 |
| 226 | Opportunities and challenges of proteomics in pediatric patients: Circulating biomarkers after hematopoietic stem cell transplantation as a successful example. Proteomics - Clinical Applications, 2014, 8, 837-850. | 1.6 | 4 |
| 227 | Iatrogenic immunodeficiency-associated lymphoproliferative disorder in a child with B-cell acute lymphoblastic leukemia. Pediatric Hematology and Oncology, 2019, 36, 309-316. | 0.8 | 4 |
| 228 | Mycobacteria-Specific T Cells May Be Expanded From Healthy Donors and Are Near Absent in Primary Immunodeficiency Disorders. Frontiers in Immunology, 2019, 10, 621. | 4.8 | 4 |
| 229 | T-Cell Therapeutics Targeting Human Parainfluenza Virus 3 Are Broadly Epitope Specific and Are Cross Reactive With Human Parainfluenza Virus 1. Frontiers in Immunology, 2020, 11, 575977. | 4.8 | 4 |
| 230 | Phase I Study to Improve Virus-Specific Immune Reconstitution After Cord Blood Transplantation Using Cord Blood-Derived Virus-Specific Cytotoxic T Lymphocytes. Blood, 2011, 118, 155-155. | 1.4 | 4 |
| 231 | Generation of Multi-Antigen Specific T Cells for Adoptive Immunotherapy of Myeloid Leukemia and Identification of MHC Class I and II-Restricted Peptides for WT1, Proteinase 3 and Human Neutrophil Elastase. Blood, 2011, 118, 2985-2985. | 1.4 | 4 |
| 232 | A biomarker panel for risk of early respiratory failure following hematopoietic cell transplantation. Blood Advances, 2022, 6, 1866-1878. | 5.2 | 4 |
| 233 | Transcriptomic analysis reveals optimal cytokine combinations for SARS-CoV-2-specific TÂcell therapy products. Molecular Therapy - Methods and Clinical Development, 2022, 25, 439-447. | 4.1 | 4 |
| 234 | T-cell therapy for cancer. Immunotherapy, 2012, 4, 347-350. | 2.0 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 235 | Highlights of the Third International Conference on Immunotherapy in Pediatric Oncology. Pediatric Hematology and Oncology, 2013, 30, 349-366. | 0.8 | 3 |
| 236 | Genomic and clinical characterization of early T-cell precursor lymphoblastic lymphoma. Blood Advances, 2021, 5, 2890-2900. | 5.2 | 3 |
| 237 | The Histone Deacetylase Inhibitor Entinostat (SNDX-275) Targets Hodgkin Lymphoma through a Dual Mechanism of Immune Modulation and Apoptosis Induction. Blood, 2010, 116, 2850-2850. | 1.4 | 3 |
| 238 | Ex vivo expanded multi-antigen specific lymphocytes for the treatment of solid tumors.. Journal of Clinical Oncology, 2018, 36, 3042-3042. | 1.6 | 3 |
| 239 | Adoptive immunotherapy for herpesviruses. , 2007, , 1318-1331. | | 2 |
| 240 | Administration of LMP-specific cytotoxic T-lymphocytes to patients with relapsed EBV-positive lymphoma post allogeneic stem cell transplant. Cytotherapy, 2015, 17, S18. | 0.7 | 2 |
| 241 | Introduction to a review series on advances in cell-based immune therapeutics in hematology. Blood, 2016, 127, 3293-3293. | 1.4 | 2 |
| 242 | Developing T-cell therapies for lymphoma without receptor engineering. Hematology American Society of Hematology Education Program, 2017, 2017, 622-631. | 2.5 | 2 |
| 243 | Malignant Lymphomas in Childhood. , 2018, , 1330-1342.e5. | | 2 |
| 244 | Using Molecular Stratification for Smart Combination Therapies. Journal of Clinical Oncology, 2021, 39, 3527-3530. | 1.6 | 2 |
| 245 | Toxicity Profile of Brentuximab Vedotin in Combination with Chemotherapy for Newly Diagnosed Patients with ALK+ ALCL: A Children's Oncology Group Study ANHL12P1. Blood, 2018, 132, 1625-1625. | 1.4 | 2 |
| 246 | Lenalidomide Treatment Enhances Immunological Synapse Formation of Cord Blood Natural Killer Cells with B Cells Derived From Chronic Lymphocytic Leukemia. Blood, 2011, 118, 1794-1794. | 1.4 | 2 |
| 247 | Improving Immune Reconstitution After Cord Blood Transplantation Using Ex Vivo Expanded Virus-Specific T Cells: A Phase I Clinical Study. Blood, 2012, 120, 224-224. | 1.4 | 2 |
| 248 | Multicenter Study of â€œoff-the-Shelfâ€•Third Party Virus-Specific T Cells (VSTs) to Treat Adenovirus (Adv), Cytomegalovirus (CMV) or Epstein Barr Virus (EBV) Infection After Hemopoietic Stem Cell Transplantation (HSCT). Blood, 2012, 120, 457-457. | 1.4 | 2 |
| 249 | BCL-2 Antagonism Sensitizes CTL-Resistant HIV Reservoirs to Elimination <i>Ex Vivo</i>. SSRN Electronic Journal, 0, , . | 0.4 | 2 |
| 250 | LMP2-Cytotoxic T Lymphocyte Therapy for Relapsed EBV Positive Lymphoma.. Blood, 2004, 104, 3276-3276. | 1.4 | 2 |
| 251 | Antigen-specific T cell responses correlate with decreased occurrence of acute GVHD in a multicenter contemporary cohort. Bone Marrow Transplantation, 2022, 57, 279-281. | 2.4 | 2 |
| 252 | Comparable transforming growth factor beta-mediated immune suppression in ex vivo-expanded natural killer cells from cord blood and peripheral blood: implications for adoptive immunotherapy. Cytotherapy, 2022, 24, 802-817. | 0.7 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 253 | Hodgkin's disease: are you the type?. Lancet, The, 2005, 365, 2162-2163. | 13.7 | 1 |
| 254 | Reply to Sackstein. Experimental Hematology, 2012, 40, 519-520. | 0.4 | 1 |
| 255 | The 2013 Educational Supplement on Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, S1. | 2.0 | 1 |
| 256 | Administration of LMP-Specific Cytotoxic T-Lymphocytes to Patients with Relapsed EBV-Positive Lymphoma Post Allogeneic Stem Cell Transplant. Biology of Blood and Marrow Transplantation, 2015, 21, S148. | 2.0 | 1 |
| 257 | Enhancing The Generation Of Adenovirus-Specific T Cells With Exercise For Immunotherapy. Medicine and Science in Sports and Exercise, 2016, 48, 86-87. | 0.4 | 1 |
| 258 | Increased Tumor Specific Cytotoxic T Cell Responses and Reversion to a Favorable Cytokine Profile after Treatment in Patients with Newly Diagnosed High Risk Hodgkin Lymphoma Treated on Children's Oncology Group Trial-AHOD1331. Blood, 2020, 136, 41-42. | 1.4 | 1 |
| 259 | Tumor Associated Antigen Specific T Cells Given in Combination with Nivolumab for the Treatment of Hodgkin Lymphoma. Blood, 2020, 136, 18-18. | 1.4 | 1 |
| 260 | Dramatic Reduction of Chronic Lymphocytic Leukemia (CLL) Cells Following Adoptive Transfer of Cord Blood (CB) Natural Killer (NK) Cells Using CB-Engrafted NOD-SCID IL2RÎ³null (NSG) Mice as a Model.. Blood, 2009, 114, 2370-2370. | 1.4 | 1 |
| 261 | Allogeneic Virus-Specific T Cells with HLA Alloreactivity Do Not Produce Graft-Versus-Host Disease In Human Subjects. Blood, 2010, 116, 1252-1252. | 1.4 | 1 |
| 262 | CD137L Reverse the Immunological Synapse Defects of Natural Killer Cells in Acute Myeloid Leukemia. Blood, 2011, 118, 246-246. | 1.4 | 1 |
| 263 | Assessment of ST2 for Risk of Death Following Graft-versus-Host Disease in the Pediatric and Adult Age Groups. SSRN Electronic Journal, 0, , . | 0.4 | 1 |
| 264 | A Participant-Derived Xenograft Model of HIV Enables Long-Term Evaluation of Autologous Immunotherapies. SSRN Electronic Journal, 0, , . | 0.4 | 1 |
| 265 | Specific Adoptive T-Cell Therapy for Viral and Fungal Infections. , 2018, , 395-411. | | 1 |
| 266 | Intensification of Chemotherapy Using a Modified BFM Backbone for Children, Adolescents and Young Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Identifies Highly Chemorefractory Patients Who Benefit from Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2021, 138, 3487-3487. | 1.4 | 1 |
| 267 | Flow-based analysis of cell division identifies highly active populations within plasma products during mixed lymphocyte cultures. Blood Transfusion, 2021, 19, 456-466. | 0.4 | 1 |
| 268 | IMMU-19. Outcomes of Pediatric Patients with High-Risk CNS Tumors Treated with Multi-tumor associated antigen specific T cell (TAA-T) therapy: the ReMIND trial. Neuro-Oncology, 2022, 24, i85-i86. | 1.2 | 1 |
| 269 | Adoptive Immunotherapy. , 0, , 920-935. | | 0 |
| 270 | Isolating cytomegalovirus-specific T cells for adoptive transfer: are we there yet?. Cytotherapy, 2010, 12, 857-858. | 0.7 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 271 | Immunologic special forces: anti-pathogen cytotoxic T-lymphocyte immunotherapy following hematopoietic stem cell transplantation. ImmunoTargets and Therapy, 2014, 3, 97. | 5.8 | 0 |
| 272 | A Change in the Editorial Office: Farewell from Catherine M. Bollard. Pediatric Hematology and Oncology, 2014, 31, 393-394. | 0.8 | 0 |
| 273 | Reply to S. Yuan et al. Journal of Clinical Oncology, 2014, 32, 2820-2821. | 1.6 | 0 |
| 274 | T-Cell Immunotherapy for Cancer. , 2015, , 389-410. | | 0 |
| 275 | Directed T-cell therapies for leukemia and lymphoma after hematopoietic stem cell transplant: beyond chimeric antigen receptors. International Journal of Hematologic Oncology, 2015, 4, 99-111. | 1.6 | 0 |
| 276 | HIV Receives a â€œOne Two Knockout Punchâ€. Molecular Therapy, 2017, 25, 566-567. | 8.2 | 0 |
| 277 | Immune therapy with cytotoxic T-lymphocytes for treatment of infections. , 0, , 611-625. | | 0 |
| 278 | Virus-Specific T Cells for Hematopoietic Stem Cell Transplantation. Current Stem Cell Reports, 2017, 3, 290-300. | 1.6 | 0 |
| 279 | Introduction to a How I Treat series on hematologic complications in pregnancy. Blood, 2020, 136, 2093-2093. | 1.4 | 0 |
| 280 | Introduction to a review series on understanding and treating primary immunodeficiency. Blood, 2020, 135, 591-591. | 1.4 | 0 |
| 281 | Preventative and Preemptive Strategies for EBV Infection and PTLD After HSCT. , 2021, , 239-251. | | 0 |
| 282 | Introduction to a review series on gene therapy and gene editing for sickle cell disease and hemophilia. Blood, 2021, 138, 913-913. | 1.4 | 0 |
| 283 | Outcome of Alternative Donor Transplantation for Severe Aplastic Anemia Can Be Comparable to Outcome with Matched Related Donors.. Blood, 2005, 106, 2052-2052. | 1.4 | 0 |
| 284 | Transplantation from Matched Unrelated Donors (MUD) for Thalassemia and Other Congenital Red Cell Disorders.. Blood, 2005, 106, 2746-2746. | 1.4 | 0 |
| 285 | The Use of Autologous LMP2-Specific Cytotoxic T Lymphocytes (CTL) for the Treatment of Relapsed EBV-Positive Hodgkin Disease and Non-Hodgkin Lymphoma.. Blood, 2005, 106, 773-773. | 1.4 | 0 |
| 286 | Generation of Influenza HA-Specific Lymphocytes from Autologous Umbilical Cord Blood-Derived Dendritic Cells.. Blood, 2007, 110, 3875-3875. | 1.4 | 0 |
| 287 | Deficient Th-1 Responses from TNFÎ±-Matured Dendritic Cells.. Blood, 2007, 110, 3839-3839. | 1.4 | 0 |
| 288 | Complete Tumor Responses in Lymphoma Patients Who Receive Autologous Cytotoxic T Lymphocytes Targeting EBV Latent Membrane Proteins. Blood, 2008, 112, 230-230. | 1.4 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 289 | The â€œSide-Populationâ€•of Human Lymphoma Cells Have Increased Chemo-Resistance, Stem-Cell Like Properties and Are Potential Targets for Immunotherapy. Blood, 2008, 112, 2620-2620. | 1.4 | 0 |
| 290 | Selective Loss of a Putative Precursor Population of B-Chronic Lymphocytic Leukemia Cells Following Immunization with hCD40L/IL-2 Expressing Autologous Tumor Cells. Blood, 2008, 112, 3172-3172. | 1.4 | 0 |
| 291 | Ex Vivo Expansion of Cord Blood Natural Killer Cells Overcomes Impaired Immune Synapse Formation and Effector Function in Acute Myeloid Leukemia. Blood, 2008, 112, 2905-2905. | 1.4 | 0 |
| 292 | Cytotoxic T Lymphocytes (CTL) Specific for Adenovirus and CMV Can Be Generated from Umbilical Cord Blood for Adoptive Immunotherapy. Blood, 2008, 112, 3505-3505. | 1.4 | 0 |
| 293 | Cytotoxic T Lymphocytes (CTL) Specific for CMV, Adenovirus, and EBV Can Be Generated From Naive T Cells for Adoptive Immunotherapy.. Blood, 2009, 114, 504-504. | 1.4 | 0 |
| 294 | Adverse Events Following Infusion of T Cells for Adoptive Immunotherapy: A 10 Year Experience.. Blood, 2009, 114, 3212-3212. | 1.4 | 0 |
| 295 | Ex Vivo IL-2 Expansion of CB-NK Cells Promotes Synergistic LFA-1 and CD2 Engagement at the NK Cell Lytic Immune Synapse; Implications for Adoptive CB-NK Cell Therapy in Acute Myeloid Leukemia.. Blood, 2009, 114, 3029-3029. | 1.4 | 0 |
| 296 | Targeting Chronic Lymphocytic Leukemia with Cord Blood NK Cells In NSG Model. Blood, 2010, 116, 2453-2453. | 1.4 | 0 |
| 297 | Antigen Presenting Cell-Mediated Ex Vivo Expansion of Human Umbilical Cord Blood Cells Yields Log-Scale Expansion of Natural Killer Cells with Anti-Myeloma Activity. Blood, 2010, 116, 2100-2100. | 1.4 | 0 |
| 298 | Anti-Viral Cytotoxic T-Lymphocyte Therapy. Blood, 2010, 116, SCI-50-SCI-50. | 1.4 | 0 |
| 299 | The Effects of Co-Stimulatory Endodomains on the Fate of T Cells Expressing a Tumor Directed Chimeric Antigen Receptor (CAR) In Human Subjects with B Cell Malignancies. Blood, 2010, 116, 3949-3949. | 1.4 | 0 |
| 300 | Towards Phase 2/3 Trials for Epstein - Barr Virus (EBV)-Associated Malignancies,. Blood, 2011, 118, 4043-4043. | 1.4 | 0 |
| 301 | Adoptive Immunotherapy with Autologous CD3/CD28-Costimulated T-Cells After Fludarabine-Based Chemotherapy in Patients with Chronic Lymphocytic Leukemia. Blood, 2011, 118, 2855-2855. | 1.4 | 0 |
| 302 | Whole genome sequencing of sporadic Burkitt lymphoma in HIV-infected and uninfected patients.. Journal of Clinical Oncology, 2013, 31, 8577-8577. | 1.6 | 0 |
| 303 | FLT Imaging Reveals Kinetics and Biology of Engraftment after Myeloablative HSCT. Blood, 2014, 124, 1147-1147. | 1.4 | 0 |
| 304 | A Novel Standardized Quantitative Suppression Assay Reveals a Diversity of Human Immune-Regulatory Cell Potency. Blood, 2014, 124, 316-316. | 1.4 | 0 |
| 305 | Adoptively-Transferred EBV-Specific T Cells to Prevent or Treat EBV-Related Lymphoproliferative Disease in Allogeneic HSCT Recipients - a Single Center Experience Spanning 22 Years. Blood, 2015, 126, 1926-1926. | 1.4 | 0 |
| 306 | Robust immune responses to SARS-CoV-2 in a pediatric patient with B-Cell ALL receiving tisagenlecleucel. Pediatric Hematology and Oncology, 2022, , 1-9. | 0.8 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 307 | Reply to R. Lakhotia et al. Journal of Clinical Oncology, 2022, , JCO2102912. | 1.6 | 0 |